Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Coherus BioSciences Inc CHRS

Healthcare Biotechnology
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and... see more

Recent & Breaking News (NDAQ:CHRS)

Coherus Announces Closing of Sale of Common Stock to Immuno-Oncology Partner Junshi Biosciences

GlobeNewswire April 20, 2021

Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma

GlobeNewswire March 3, 2021

Coherus Management to Present at Upcoming Investor Conferences

GlobeNewswire February 25, 2021

Coherus BioSciences Reports Fourth Quarter and Full Year 2020 Financial Results

GlobeNewswire February 24, 2021

Coherus BioSciences to Report Fourth Quarter and Full Year 2020 Financial Results on February 24th

GlobeNewswire February 18, 2021

Coherus BLA Filing for Adalimumab Biosimilar Candidate Accepted by FDA for Review

GlobeNewswire February 17, 2021

Coherus Announces CFO Transition Plans

GlobeNewswire February 16, 2021

Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences

GlobeNewswire February 2, 2021

Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada

GlobeNewswire February 1, 2021

Coherus BioSciences to expand late-stage pipeline to immuno-oncology with in-license of Junshi Biosciences' PD-1, toripalimab, in United States and Canada

GlobeNewswire February 1, 2021

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire January 22, 2021

Coherus BioSciences Appoints Alan Mendelson and Mark Stolper to Board of Directors

GlobeNewswire January 7, 2021

Coherus BioSciences Management to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2021

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire December 21, 2020

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire November 20, 2020

Coherus BioSciences Reports Third Quarter 2020 Financial Results

GlobeNewswire November 5, 2020

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire October 16, 2020

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire September 18, 2020

Coherus BioSciences Announces New Employment Inducement Grants

GlobeNewswire August 21, 2020

Coherus BioSciences Reports Second Quarter 2020 Financial Results

GlobeNewswire August 6, 2020